I wouldn't say patients achieving SD, PR and CR early in Ph1 clinical trial as "no significant data produced". BP very rarely do a T/O of IP so early in the development phase and Azer-Cel was purchase for CD19 where preclinical trial combination with CF33 was done in 2020. So, was the market "right" when the pps dropped to 4c last time before the beautiful data for VAXINIA was released and the pps rerate to high of 15c and stayed at 10c for many months???? Yes, where is this further beautiful data with the market not valuing the previous beautiful data for now and any development of Azer-Cel????
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)